NCT06735820View on ClinicalTrials.gov

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2028

Conditions
Malignant Peripheral Nerve Sheath Tumor (MPNST)Neurofibromatosis 1 (NF1)Atypical Neurofibroma
Interventions
DRUG

APG-115

Combination therapy of APG-115 and Selumetinib

DRUG

Selumetinib

Combination therapy of APG-115 and Selumetinib

Trial Locations (1)

20010

Children's National Hospital, Washington D.C.

Sponsors
All Listed Sponsors
collaborator

Children's National Research Institute

OTHER

lead

AeRang Kim

OTHER